Table 6. Summary of Tumor Response in Studies of First-line Treatment With EGFR-TK Inhibitors (Single Agent) for Advanced NSCLC

Study ID Diagnosis
(no. of patients)
[agent]		 Sub-groups N Survival from start
of treatment		 Tumor response
Median
(months)		 1-year (%) % CR % PR % SD % DP % NE
All NSCLC
Niho, et al., 200411 NSCLC
(37)
[Gefitinib]		 - - 37 - - - - 0 27 - - - - - -
Giaccone, et al., 200512 NSCLC
(53)
[Erlotinib]		 - - 53 - - - - 2 23 30 32 13
Kasahara, et al., 200513 NSCLC
(30)
[Gefitinib]		 - - 30 10 43.3 0 33 30 37 - -
Suzuki, et al., 200514 NSCLC
(34)
[Gefitinib]		 - - 34 - - - - 0 26 - - - - - -
Reck, et al., 200515 NSCLC
(58)
[Gefitinib]		 - - 58 - - - - 2 3 40 48 - -
D'Addario, et al., 200516 NSCLC
(63)
[Gefitinib]		 - - 63 10 - - 2 8 27 57 6
Lee, et al., 200517 NSCLC
(55)
[Gefitinib]		 - - 55 Not
reached		 76.1 4 57 11 28 - -
BAC
West, et al., 200418 NSCLC
(138)
[Gefitinib]		 Chemo-naive
Previous treatment
(26%)		 67
21		 12
10		 ~50
~50		 6
0		 15
10		 - - - - - -
Kris, et al., 200419 NSCLC
(69)
[Erlotinib]		 - - 59 Median not
reached		 58 - - 25
(15-38)		 - - - - - -
Elderly
Jackman, et al., 200521 NSCLC
(58)
[Erlotinib]		 - - 66 11 - - 0 12 48 39 - -
Poor PS
Dickson, et al., 200422 NSCLC
(25)
[Gefitinib]		 - - 18 Median not
reached		 Follow up
< 1 year		 - - - - 61 39 - -

Abbreviations: BAC = bronchoalveolar carcinoma; CR = complete response; DP = disease progression; EGFR-TK = epidermal growth factor receptor tyrosine kinase; NE = not evaluable; NSCLC = non-small cell lung cancer; no. = number; PR = partial response; SD = stable disease.

Return to Document